

PROFESSIONAL INFORMATION

SCHEDULING STATUS

S4

1 NAME OF THE MEDICINE

PRYDOSTRIN 60 mg sugar coated tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 60 mg of the dimethylcarbamic-ester of 1-methyl-3-hydroxypyridinium bromide (pyridostigmine bromide).

Contains sugar: Lactose monohydrate 120 mg per tablet.

For full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Sugar coated tablets.

Reddish brown round biconvex sugar-coated tablet plain from both sides.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Myasthenia gravis.

4.2 Posology and method of administration

Posology

Adults: 1 - 3 60 mg tablets two to four times daily, or higher doses if required.

Children: 7 mg/kg body-mass daily at four hourly intervals.

It is important to remember that the dosage must be individually titrated. No response to a specific dosage could be due to underdosage or overdosage.

Usually in the case of too large a dose given too frequently, side effects of the

muscarinic and/or nicotinic type will manifest (see section 4.8).

Method of administration

For oral use.

4.3 Contraindications

- Hypersensitivity to pyridostigmine or to any of the excipients of PRYDOSTRIN (see section 6.1).
- Mechanical intestinal or urinary obstruction.

4.4 Special warnings and precautions for use

Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. Overdosage may result in cholinergic crisis, a state characterised by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme muscle weakness, and thus may be difficult to distinguish from cholinergic crisis on a symptomatic basis.

Differential diagnosis can be aided by the Tensilon® (edrophonium chloride) test. If 0,1 ml (1 mg) or at most 0,2 ml (2 mg) of Tensilon® (edrophonium chloride) is given intravenously, a marked improvement indicates myasthenic crisis. Any other response, whether equivocal or exacerbation of symptoms, must be considered to be cholinergic.

The treatment of the two conditions obviously differs radically. Whereas the presence of myasthenic crisis suggests the need for more intensive anticholinesterase therapy, the diagnosis of cholinergic crisis calls for the prompt withdrawal of all medicines of this type and institution of appropriate supportive measures, including respiratory assistance. The immediate use of atropine in

cholinergic crisis is also recommended.

Atropine may also be used to abolish or obtund gastrointestinal side effects or other muscarinic reactions. Care should be observed in the use of atropine for counteracting side effects; such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis.

Differentiation of myasthenic and cholinergic crisis

The patient with myasthenic crisis will often have a history of intervening infection, emotional trauma, perhaps a relationship to the menstrual cycle or cessation of medication. The usual dose of the medicine becomes ineffective and increased weakness or side reactions do not occur after taking medication.

A cholinergic crisis may begin in a similar manner but the patient keeps increasing the amount and frequency of medication, with less effect and more side reactions, especially increased secretions with gastrointestinal activity.

The patient in cholinergic crisis is weak, as in myasthenic crisis, but there is usually pallor, a cold clammy skin, often accompanied by hypertension, bradycardia, miosis, excessive salivation and perspiration and muscular fasciculation.

PRYDOSTRIN is mainly excreted unchanged by the kidney. Therefore lower doses may be required in patients with renal disease and treatment should be based on titration of medicine dosage effect.

Extreme caution is required when administering PRYDOSTRIN to patients with obstructive respiratory diseases like bronchial asthma and chronic obstructive pulmonary diseases (COPD).

Care should be taken in patients with:

- Dysrhythmias such as bradycardia and AV block (elderly patients may be more susceptible to dysrhythmias than the young adult)

- Recent coronary occlusion
- Hypotension
- Vagotonia
- Peptic ulcer
- Epilepsy
- Parkinsonism
- Hyperthyroidism
- Renal impairment

When relatively large doses of pyridostigmine bromide are taken by myasthenic patients it may be necessary to give atropine or other anti-cholinergic medicines to specifically counteract the muscarinic effects of pyridostigmine while maintaining its nicotinic effect.

PRYDOSTRIN should be given with caution to elderly patients and to patients with pre-existing conduction disturbances.

Note: certain antibiotics, especially neomycin, streptomycin and kanamycin have a mild definite non-depolarizing blocking action which may accentuate neuromuscular block. These antibiotics should only be used in the myasthenic patient when definitely indicated and then with careful observation to adjust anticholinesterase dosage.

PRYDOSTRIN contains lactose monohydrate. Patients with the rare hereditary conditions of galactose intolerance e.g. galactosaemia, the Lapp lactase deficiency or glucose-galactose malabsorption should not take PRYDOSTRIN.

4.5 Interaction with other medicines and other forms of interaction

Immunosuppressant medicines

The requirement for pyridostigmine bromide may be decreased by concomitant use when additional therapy (corticosteroids or immune-suppressant medicines) is given. Nevertheless, a new addition of corticosteroids may initially aggravate the symptoms of myasthenia gravis.

Thymectomy

The need for PRYDOSTRIN dosing may be decreased after thymectomy.

Methylcellulose

Methylcellulose and medicines containing methylcellulose as excipients can completely inhibit absorption of pyridostigmine bromide.

Antimuscarinics

Atropine and Hyoscine antagonise the muscarinic effects of pyridostigmine bromide. It should be noted that the slower gastro-intestinal motility caused by these medicines may affect the absorption of pyridostigmine bromide.

Muscle relaxants

Pyridostigmine bromide antagonises the effect of non-polarising muscle relaxants (e.g. pancuronium and vecuronium). Pyridostigmine bromide may prolong the effect of depolarising muscle relaxants (e.g. suxamethonium).

Others

Aminoglycoside antibiotics, local and some general anaesthetics, antidysrhythmic medicines, and other medicines that interfere with neuromuscular transmission may interact with pyridostigmine bromide.

4.6 Fertility, pregnancy and lactation

Pregnancy

Safety in pregnancy has not been established.

Breastfeeding

Safety in lactation has not been established.

Fertility

No data is available.

4.7 Effects on ability to drive and use machines

Due to miosis and accommodation disorders caused by pyridostigmine bromide or an inadequate treatment of Myasthenia gravis, PRYDOSTRIN may impair visual acuity and consequently the ability to react as well as the ability to drive and use machines.

4.8 Undesirable effects**a. Summary of the safety profile**

Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness. Skin rash may occur.

As with all cholinergic medicines, PRYDOSTRIN may have unwanted functional effects on the autonomic nervous system.

Muscarinic-like adverse effects may be exhibited as nausea, vomiting, diarrhoea, abdominal cramps, increased peristaltic and increased bronchial secretion, salivation, bradycardia and miosis and diaphoresis.

The primary nicotinic effects are muscle spasms, fasciculation and muscular weakness.

b. Tabulated summary of adverse reactions

Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: frequent, less frequent and frequency unknown.

System organ class	Frequency	Adverse reactions
Immune system disorders	Frequency unknown	Medicine hypersensitivity
Nervous system disorders	Frequency unknown	Syncope
Eye disorders	Frequency unknown	Miosis, increased lacrimation, accommodation disorders (e.g. blurred vision)
Cardiac disorders	Frequency unknown	Dysrhythmia (incl. bradycardia, tachycardia, AV Block) as well as syncope and hypotension, Prinz metal angina
Vascular disorders	Frequency unknown	Flushing, hypotension
Respiratory, thoracic and mediastinal disorders	Frequency unknown	Increased bronchial secretion combined with bronchoconstriction
Gastrointestinal disorders	Frequency unknown	Nausea, vomiting, diarrhoea, abdominal cramps, gastrointestinal hypermotility, salivary hypersecretion, abdominal symptoms (e.g. discomfort pain, cramps)
Skin and subcutaneous	Less frequent	Rash (disappears usually soon

System organ class	Frequency	Adverse reactions
tissue disorders		after ceasing of medication. Bromide containing medicines should no longer be used)
	Frequency unknown	Hyperhidrosis, urticarial
Musculoskeletal and connective tissue disorders	Frequency unknown	Increased muscle weakness, fasciculation (muscle twitching), tremors, and muscle cramps or muscle hypotonia.
Renal and urinary disorders	Frequency unknown	Urinary urgency

Because these symptoms may be an indication of cholinergic crisis, the medical practitioner should be notified immediately to clarify the diagnosis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the Med Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on SAHPRA website.

4.9 Overdose

In the event of an overdose, side effects can be precipitated and/or be of increased severity (see section 4.8).

As PRYDOSTRIN is excreted mainly by the kidneys, caution is advised in cases of renal function impairment.

The signs and symptoms of overdosage are due to muscarinic and nicotinic actions. Its muscarinic effects consist of abdominal cramps, increased peristalsis, diarrhoea, nausea and vomiting, increased bronchial secretions, salivation, diaphoresis and miosis. The nicotinic effects are muscular cramps, fasciculations and general weakness. Bradycardia and hypotension may occur if overdosage is excessive. Skin rashes due to sensitivity to bromide ion have been reported. Overdosage with decreased therapeutic effect must be differentiated from myasthenia gravis.

Suggested treatment of overdosage:

PRYDOSTRIN treatment must be stopped immediately.

Artificial ventilation should be instituted if respiration is severely depressed.

The muscarinic effects are the most serious and may be controlled by atropine.

Nicotinic effects may be treated symptomatically.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacological classification: A.5.3 Cholinergics

Pharmacotherapeutic group: Nervous system, parasympathomimetics, anticholinesterases, pyridostigmine, ATC code: N07AA02

Pyridostigmine is an orally reversible cholinesterase inhibitor. It has a slower onset and longer duration of action than neostigmine.

5.2 Pharmacokinetic properties

Oral pyridostigmine bromide is poorly absorbed. Maximum plasma concentrations occur at 1 to 2 hours and it is eliminated by the kidney largely unchanged with a half-life of 3 to 4 hours.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

Colloidal anhydrous silica

Lactose monohydrate

Magnesium stearate

Povidone

Pregelatinized starch

Talc

Tablet coating:

Opadry SGR 230U190010 translucent contains:

Glyceryl monostearate

Hypromellose

Macrogol/PEG

Medium chain triglycerides

Sucrose

Talc

Opadry SGR 231U25004 red contains:

Hypromellose

Iron oxide red

Iron oxide yellow

Macrogol/PEG

Medium chain triglycerides

Polyvinyl alcohol

Sucrose

Talc

Titanium dioxide

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months.

6.4 Special precautions for storage

Store at or below 30 °C.

Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

Heat sealed ALU/ALU blisters, each containing 10 tablets packed in a cardboard box.

Pack size: 150 tablets.

or

White, opaque HDPE bottles, 38 mm neck, with white, opaque polypropylene child-resistant closure, packed in a cardboard box.

Pack size: 150 tablets.

6.6 Special precautions for disposal and other handling

No special requirements.

7 HOLDER OF CERTIFICATE OF REGISTRATION

Juno Pharma SA (Pty) Ltd

Address: 3 Gwen Lane, 4th Floor, Sandton, 2031.

Contact No.: +27 (0)10 594 5610

PV Email Address: pv@trinitypharma.co.za

8 REGISTRATION NUMBER

580230

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

22 July 2025

10 DATE OF REVISION OF THE TEXT

To follow